Search results
Half Of Dementia Cases Can Be Curbed By Addressing These Key Risk Factors
NDTV· 1 hour agoMillions of cases of dementia could be prevented or delayed by reducing a range of risk factors such...
Vaccinex’s Phase Ib/II trial for Alzheimer’s treatment hits primary endpoint
Clinical Trials Arena· 12 hours agoVaccinex states a drug that can slow progression of this could significantly extend a productive...
Biogen, Beckman Coulter and Fujirebio partner to develop Alzheimer’s Tau blood test
Medical Device Network· 14 hours agoBiogen, Beckman Coulter and Fujirebio have partnered to identify and develop new blood-based...
Vertex’s pain drug gets speedy FDA review; Keytruda hits a sales milestone
BioPharma Dive· 17 hours agoQuarterly sales of Merck’s immunotherapy crested $7 billion for the first time. Elsewhere, Fibrogen...
Benefit of Eisai and Biogen's Alzheimer's drug increases over time, studies suggest - ET HealthWorld...
The Economic Times· 1 day agoChicago: The benefit of Eisai and Biogen's Alzheimer's drug Leqembi in patients with early-stage...
Cognition Therapeutics’ stock dips 43% following trial results for Alzheimer’s candidate
Clinical Trials Arena· 2 days agoEli Lilly received approval from the US Food and Drug Administration (FDA) for its amyloid-targeting...
JMC-G commissioner issues order for approval of civic body meeting agendas | Jaipur News - Times of...
The Times of India· 2 days agoJaipur: JMC-Greater administration has issued an order instructing officials to ensure that agendas...
AAIC 2024: the evolution of Alzheimer’s clinical trials
Pharmaceutical Technology· 2 days agoThis could improve adverse effects and help with chronic use, he added. The availability of...
EU CHMP snubs Biogen and Eisai’s Alzheimer’s therapy Leqembi
Pharmaceutical Technology· 2 days agoThe European Medicines Agency (EMA) has halted Eisai and Biogen’s expansion plan to launch its...
Alzheimer’s Disease: Some trials to watch over the next year
Clinical Trials Arena· 3 days agoAs against previously approved anti-amyloid therapies like lecanemab marketed as Leqembi, and Biogen...